New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export HIND’s income statement to Excel — free account
Vyome Holdings, Inc.
HINDVyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.
- Revenue
- +67.6%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
1.20
0.25
−17.24%
Follow HIND
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 3 | 10 | 9 | 3 | 11 | 14 | 11 | 9 | 0 | 0 | 0 | (23.1%) | 0 | 0 | — | (20.9%) | |
| Gross margin, % | 17.21 | 51.29 | 40.41 | 10.09 | 55.42 | 61.38 | 60.52 | 63.93 | 75.91 | 68.44 | 50.39 | +51.2 pt | ||||||
| EBT | (20) | (35) | (37) | (24) | (22) | (63) | (47) | (11) | (1) | (10) | (4) | n/m | ||||||
| EBT margin, % | (603.21) | (350.67) | (410.72) | (721.61) | (193.03) | (466.32) | (414.54) | (130.62) | (563.45) | (3,277.35) | (2,555.61) | (2,674.1) pt | ||||||
| Net income | (20) | (35) | (37) | (24) | (22) | (63) | (46) | (11) | (1) | (10) | (4) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.80 | 0.59 | 4.78 | 0.70 | 2.89 | — | 112,400.00 | 8,678.00 | 1,065.98 | 0.15 | 0.02 | (17.1%) | |||||
| Earnings | (4.85) | (2.08) | (19.63) | (5.03) | (5.54) | (1,453,488.00) | — | (11,104.65) | (6,001.39) | (4.86) | (0.59) | n/m | ||||||
| Cash flow | (4.59) | (1.83) | (15.46) | (4.86) | (2.19) | — | (219,020.00) | (16,960.00) | (2,548.13) | (1.73) | (0.64) | n/m | ||||||
| Capex | (0.08) | (0.06) | (0.67) | (0.04) | (0.10) | — | (920.00) | (10.00) | 1.24 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (4.67) | (1.89) | (16.13) | (4.90) | (2.29) | — | (219,940.00) | (16,970.00) | (2,546.89) | (1.73) | (0.64) | n/m | ||||||
| Book value | 15.23 | 2.10 | 6.88 | 3.37 | 3.71 | — | 36,610.00 | 6,663.00 | (18,219.92) | 1.74 | 0.93 | (21.4%) | ||||||
| Shares, m | 4 | 17 | 2 | 5 | 4 | 0 | 0 | 0 | 0 | 2 | 7 | (7.2%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | |||||
| P/S | 99,162,871.79 | 104,890,153.82 | 3,767,622.90 | 2,371,432.79 | 451,056.17 | 0.00 | 0.81 | 0.18 | 0.02 | 63.32 | 55.90 | 21,064,320.2 | ||||||
| P/B | 5,232,246.70 | 29,615,270.27 | 2,616,093.39 | 490,925.04 | 351,797.04 | 0.00 | 2.48 | 0.23 | 0.00 | 5.38 | 1.31 | 3,830,634.1 | ||||||
| EV/Sales | 99,162,852.46 | 104,890,150.35 | 3,767,621.38 | 2,371,428.85 | 451,057.04 | (1.66) | 0.47 | (0.35) | 0.88 | 48.50 | 12.73 | 21,064,315.8 | ||||||
| EV/FCF | (17,061,843.73) | (32,838,000.14) | (1,116,400.41) | (337,409.28) | (570,077.57) | 1.43 | (0.24) | 0.18 | (5.83) | (4.14) | (0.43) | (5,192,374.0) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (19) | (31) | (29) | (23) | (9) | (15) | (22) | (17) | (1) | (4) | (4) | n/m | |||||
| Capex | 0 | (1) | (1) | 0 | 0 | 0 | 0 | 0 | 0 | — | — | n/m | ||||||
| Free cash flow | (20) | (32) | (31) | (23) | (9) | (16) | (22) | (17) | (1) | (4) | (4) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 73 | 42 | 11 | 14 | (3) | 22 | 2 | 7 | (5) | 3 | 6 | (30.7%) | |||||
| Net debt | (66) | (34) | (14) | (13) | 10 | (23) | (4) | (5) | 3 | (5) | (7) | n/m | ||||||
| Shareholders’ equity | 64 | 35 | 13 | 16 | 14 | 44 | 4 | 7 | (4) | 4 | 7 | (27.1%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (44.02) | (52.72) | (89.55) | (93.25) | (75.30) | (140.96) | (145.16) | (104.44) | (24.04) | (260.50) | (48.02) | (216.5) pt | |||||
| ROIC | 0.00 | (3,384.94) | 0.00 | (496.88) | (32.10) | (165.96) | 0.00 | (456.96) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (446.59) | (69.94) | (155.04) | (163.53) | (142.60) | (214.71) | (192.58) | (220.59) | (127.42) | 3,262.96 | (71.85) | +3,709.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 11 | 137 | 103 | 34 | 2 | 47 | 40 | 31 | 18 | 18 | — | +5.6% | |||||
| Revenue/emp, $m | 0.31 | 0.07 | 0.09 | 0.10 | 5.65 | 0.29 | 0.28 | 0.28 | 0.01 | 0.02 | — | (27.2%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Vyome Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AEON AEON Biopharma, Inc. | $11.2M | — (loss-making) | — | — | n/m | −120.53% (below 0%: shrinking) | — | — | Compare |
| PBM Psyence Biomedical Ltd. | $10.9M | 0.1× | — | — | n/m | −1,628.07% (below 0%: shrinking) | — | — | Compare |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $10.6M | — | — | — | — | — | — | — | Compare |
| HIND Vyome Holdings, Inc. | $10.2M | — (loss-making) | — (loss-making) | +67.63% (above 0%: growing) | n/m | +63.50% (above 0%: growing) | 46.21% | (1,760.52%) | |
| LSTA Lisata Therapeutics, Inc. | $9.8M | — (loss-making) | — (loss-making) | — | n/m | −279.44% (below 0%: shrinking) | 100.00% | (3,080.00%) | Compare |
| BIVI BioVie Inc. | $9.8M | — (loss-making) | — | — | n/m | +3.92% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LEXX Lexaria Bioscience Corp. | $9.5M | — (loss-making) | — (loss-making) | — | n/m | +53.90% (above 0%: growing) | 100.00% | (7,259.50%) | Compare |
| TCRX TScan Therapeutics, Inc. | $9.4M | — (loss-making) | — (loss-making) | −76.66% (below 0%: shrinking) | n/m | +19.98% (above 0%: growing) | 100.00% | (5,636.69%) | Compare |
| GDTC CytoMed Therapeutics Limited | $9.2M | — (loss-making) | — (loss-making) | — | — | — | 0.00% | — | Compare |
| Median of peers | $9.8M | — | — | — | — | −58.31% | 100.00% | (4,358.34%) |
Pay and ownership Proxy statement filed Mar 31, 2026
Ownership
Directors and executive officers, together
33.00%
MNI Ventures
14.26%
Navam Capital Private Limited
10.28%
Krishna Gupta
8.28%
Shiladitya Sengupta
8.17%
Venkat Nelabhotla
8.06%
Iron Pillar Fund I Ltd.
6.48%
Mohanjit Jolly
6.48%
Hunter Ventures Limited
5.83%
Man Kwon Lam
5.58%
Felix Kar Chung Lee
5.58%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Vyome Holdings, Inc. (HIND) Latest News
- Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School Business Wire
- Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market Business Wire
- Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
- Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet Business Wire
- Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity Business Wire
- Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 Business Wire
- Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 Business Wire
- Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... GuruFocus.com
- Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase Business Wire
- Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months Business WireSimply Wall St.Simply Wall St.
20 more headlines
- Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
- Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company Business Wire
- Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity Business Wire
- Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results Business Wire
- BC-Most Active Stocks Associated Press Finance
- Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study Business Wire
- We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate
- Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company Business Wire
- Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
- Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program Business Wire
- Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing Business Wire
- Vyome Holdings Announces Results of Annual Shareholder Meeting Business Wire
- Vyome Holdings Acquires MIT AI Spinout Oculo Health
- Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity Business Wire
- Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
- Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity Business Wire
- Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio
- Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell Business Wire
- Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow Business Wire
- Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND Business Wire